Last reviewed · How we verify
Cannabidiol (CBD) Oil Capsules
Cannabidiol (CBD) Oil Capsules is a Phytocannabinoid Small molecule drug developed by McMaster University. It is currently in Phase 3 development for Epilepsy (seizure disorders), Anxiety disorders, Chronic pain.
Cannabidiol modulates endocannabinoid signaling and multiple non-cannabinoid receptors to produce anti-inflammatory, anxiolytic, and neuroprotective effects.
Cannabidiol modulates endocannabinoid signaling and multiple non-cannabinoid receptors to produce anti-inflammatory, anxiolytic, and neuroprotective effects. Used for Epilepsy (seizure disorders), Anxiety disorders, Chronic pain.
At a glance
| Generic name | Cannabidiol (CBD) Oil Capsules |
|---|---|
| Sponsor | McMaster University |
| Drug class | Phytocannabinoid |
| Target | CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multi-target) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Psychiatry, Immunology |
| Phase | Phase 3 |
Mechanism of action
CBD acts as a negative allosteric modulator of CB1 and CB2 receptors, while also interacting with serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), and other targets. This multi-target activity reduces neuroinflammation, modulates immune responses, and may provide neuroprotection without the psychoactive effects associated with THC.
Approved indications
- Epilepsy (seizure disorders)
- Anxiety disorders
- Chronic pain
- Inflammation-related conditions
Common side effects
- Fatigue
- Diarrhea
- Changes in appetite
- Hepatic enzyme elevation
- Drug-drug interactions via CYP3A4/CYP2C19
Key clinical trials
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- Cannabidiol and Alcohol Use Disorder Phenotypes (PHASE2)
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial (PHASE2)
- CBD, Nutrient Metabolism and Energy Intake (NA)
- A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions (PHASE1)
- Cannabidiol's Role in Dementia Management (PHASE2, PHASE3)
- Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabidiol (CBD) Oil Capsules CI brief — competitive landscape report
- Cannabidiol (CBD) Oil Capsules updates RSS · CI watch RSS
- McMaster University portfolio CI
Frequently asked questions about Cannabidiol (CBD) Oil Capsules
What is Cannabidiol (CBD) Oil Capsules?
How does Cannabidiol (CBD) Oil Capsules work?
What is Cannabidiol (CBD) Oil Capsules used for?
Who makes Cannabidiol (CBD) Oil Capsules?
What drug class is Cannabidiol (CBD) Oil Capsules in?
What development phase is Cannabidiol (CBD) Oil Capsules in?
What are the side effects of Cannabidiol (CBD) Oil Capsules?
What does Cannabidiol (CBD) Oil Capsules target?
Related
- Drug class: All Phytocannabinoid drugs
- Target: All drugs targeting CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multi-target)
- Manufacturer: McMaster University — full pipeline
- Therapeutic area: All drugs in Neurology, Psychiatry, Immunology
- Indication: Drugs for Epilepsy (seizure disorders)
- Indication: Drugs for Anxiety disorders
- Indication: Drugs for Chronic pain
- Compare: Cannabidiol (CBD) Oil Capsules vs similar drugs
- Pricing: Cannabidiol (CBD) Oil Capsules cost, discount & access